# Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence

> **NCT04200547** · NA · TERMINATED · sponsor: **University Hospital, Montpellier** · enrollment: 42 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **OTHER:** Immunomonitoring-based follow-up
- **OTHER:** Standard follow-up

## Key facts

- **NCT ID:** NCT04200547
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-29
- **Primary completion:** 2024-06-29
- **Final completion:** 2024-06-29
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** The recruitment of participants was no longer sufficient to continue the study.
- **Last updated:** 2025-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200547, "Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04200547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*